Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies

Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies

Source: 
BioSpace
snippet: 

Lyndra Therapeutics and Gilead Sciences have entered a partnership collaboration to develop and market ultra-long-acting oral HIV therapies. Gilead will pick up exclusive rights to Lyndra’s long-acting drug platform.